Zymeworks Inc. (ZYME)

CA — Healthcare Sector
Peers: MAZE  ARDX  SYRE  PHVS  NTLA  BCRX  IMNM  TRVI  WVE  UPB 

Automate Your Wheel Strategy on ZYME

With Tiblio's Option Bot, you can configure your own wheel strategy including ZYME - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ZYME
  • Rev/Share 1.4105
  • Book/Share 4224.2635
  • PB 0.0056
  • Debt/Equity 0.0591
  • CurrentRatio 6.9384
  • ROIC -0.0573

 

  • MktCap 1768259558.0
  • FreeCF/Share -300.7579
  • PFCF -0.0776
  • PE -0.0907
  • Debt/Assets 0.0476
  • DivYield 0
  • ROE -0.2448

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 5
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Upgrade ZYME Wells Fargo Equal Weight Overweight -- $33 Dec. 12, 2025
Initiation ZYME Citizens JMP -- Mkt Outperform -- $32 Dec. 3, 2025
Resumed ZYME Wells Fargo -- Equal Weight -- $15 Oct. 24, 2025
Upgrade ZYME H.C. Wainwright Neutral Buy -- $26 Oct. 14, 2025
Initiation ZYME B. Riley Securities -- Buy -- $30 Oct. 10, 2025
Initiation ZYME TD Cowen -- Buy -- -- May 20, 2025
Upgrade ZYME JP Morgan Neutral Overweight -- $18 Dec. 16, 2024

News

Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025
ZYME
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral

VANCOUVER, British Columbia, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will report its fourth quarter and full year 2024 financial results after market close on March 5, 2025. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on March 5, 2025 at 4:30 pm Eastern Time (ET).

Read More
image for news Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025

About Zymeworks Inc. (ZYME)

  • IPO Date 2017-04-28
  • Website https://www.zymeworks.com
  • Industry Biotechnology
  • CEO Kenneth H. Galbraith
  • Employees 299

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.